Oromucosal immunomodulation as clinical spectrum mitigating factor in SARS-CoV-2 infection

Area of Science:

• Immunology
• Virology
• Infectious Diseases

Background:

• Mucosal immunity plays a critical role in the immune response to SARS-CoV-2.
• Early viral replication in the upper respiratory tract presents an opportunity for intervention.
• Failure of the innate immune response can lead to disease progression and ineffective adaptive immunity.

Purpose of the Study:

• To explore immunological strategies for counteracting SARS-CoV-2 pathogenicity.
• To investigate the potential of enhancing mucosal immunity against SARS-CoV-2.
• To identify methods for activating local immune responses without inducing harmful inflammation.

Main Methods:

• Review of existing evidence on mucosal immunity and SARS-CoV-2.
• Analysis of viral replication dynamics in the upper respiratory tract.
• Exploration of immunomodulation as a therapeutic approach.

Main Results:

• An effective mucosal innate immune response is crucial for controlling SARS-CoV-2.
• Immunomodulation may enhance local immunity without causing cytokine response syndrome.
• Early immune activation at the oropharyngeal mucosa could alert the adaptive immune system.

Conclusions:

• Enhancing early mucosal immunity is a promising strategy against SARS-CoV-2.
• Immunomodulation offers a potential path to boost local immunity safely.
• Further research into immunotherapeutic management could mitigate COVID-19 severity.